Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > On TV

<< Previous

Bullboard Posts

Next >>

Comment by 99942Apophison Jun 27, 2023 12:58pm

137 Views

Post# 35516642

RE:RE:RE:RE:On TV

Eoganacht wrote: With zero serious adverse effects attributed to the treatment after 60 patients treated, with the lower price tag (presumably), with the ease of administration (one or two treatments that can be delivered by a urologist), and with unrivalled long term efficacy compared to approved treatments (likely more than double that of Keytruda) it is difficult to imagine that TLD1433 PDT is not on the way to becoming the preferred treatment for BCG-unresponsive high grade NMIBC.

In the most recent MD&A Theralase modestly notes:

"In 2016, Kamat et al. stated in the Journal of Clinical Oncology that the International Bladder Cancer Group (“IBCG”) recommended that, “Single-arm designs may be relevant for the BCG-unresponsive population. Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumors) of at leastIn 2016, Kamat et al. stated in the Journal of Clinical Oncology that the International Bladder Cancer Group (“IBCG”) recommended that, “Single-arm designs may be relevant for the BCG-unresponsive population. Here, a clinically meaningful initial complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumors) of at least 50% at 6 months, 30% at 12 months, and 25% at 18 months is recommended.”

The interim clinical data presented below meets or exceeds these IBCG guidelines."

TLD1433 PDT so far has 53% at 6 months, 36% at 12 months, and 33% at 15 months and is getting better continuously.

99942Apophis wrote: I am not medically knowledgeable but I do know that with big pharmas they tend to have an abundance of Adverse Effects and high costs.
Theralase's treatment remains in my opinion as very attractive to the destruction of cancer. Question still remains how many of the big Pharmaceuticals will want to team up in a combo to Theralase with their current treatments and also down the road as a combination treatment in their future vaccine?